Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept.
Withdrawal of selexipag was found safe, while discontinuation of parenteral treprostinil was feasible only in a subset of patients. The article was published in the European Respiratory Journal as a Research letter and is not open access, these are the only news publicly available and shareable at this time.
Citation
Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension, Karen M Olsson Jan Fuge, Da-Hee Park, Jan C. Kamp, Marius M. Hoeper, European Respiratory Journal 2025 2500064; DOI: https://doi.org/10.1183/13993003.00064-2025
Read more at this link on the ERS website